Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$4.31
-1.0%
$4.22
$1.89
$5.82
$1.29B0.655.02 million shs1.86 million shs
Evotec AG stock logo
EVO
Evotec
$3.55
+1.7%
$3.96
$2.84
$5.64
$1.26B1.6794,769 shs19,137 shs
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
$6.23
-3.6%
$5.07
$2.23
$17.41
$290.29M2.83872,211 shs369,470 shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$38.14
+18.4%
$28.78
$16.16
$38.83
$1.56B0.8264,050 shs814,852 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-0.46%+4.32%-11.59%+113.24%+66.67%
Evotec AG stock logo
EVO
Evotec
0.00%-2.24%-18.08%-7.67%-8.16%
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-1.07%-5.69%+39.22%+74.12%-58.40%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
-1.35%+3.40%+11.34%+30.58%+52.90%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
2.2858 of 5 stars
3.51.00.00.02.63.30.0
Evotec AG stock logo
EVO
Evotec
1.5842 of 5 stars
3.32.00.00.02.00.00.6
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
2.2887 of 5 stars
3.32.00.00.02.61.70.6
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
3.4341 of 5 stars
0.92.02.51.12.13.32.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
3.00
Buy$8.0085.83% Upside
Evotec AG stock logo
EVO
Evotec
2.50
Moderate Buy$5.4052.11% Upside
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
2.64
Moderate Buy$30.40388.04% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.83
Reduce$24.40-36.02% Downside

Current Analyst Ratings Breakdown

Latest FDMT, PAHC, ABCL, and EVO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2025
Evotec AG stock logo
EVO
Evotec
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $7.00
8/14/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
8/12/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$44.00 ➝ $38.00
8/12/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
8/8/2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $7.00
8/1/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
7/29/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (D-) ➝ Sell (D-)
7/14/2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$5.00 ➝ $10.00
7/12/2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (D-)
7/7/2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/7/2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$5.00
(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$28.83M44.62N/AN/A$3.37 per share1.28
Evotec AG stock logo
EVO
Evotec
$862.40M1.46N/AN/A$2.70 per share1.31
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
$40K7,272.36N/AN/A$9.01 per share0.69
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.19B1.30$2.47 per share15.44$6.34 per share6.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$162.86M-$0.55N/AN/AN/A-511.88%-16.17%-12.24%11/3/2025 (Estimated)
Evotec AG stock logo
EVO
Evotec
-$212.18MN/A0.00N/AN/A-20.14%-16.94%-8.14%11/5/2025 (Estimated)
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-$160.87M-$3.53N/AN/AN/A-594,375.81%-40.15%-36.43%11/12/2025 (Estimated)
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$2.42M$0.7849.2818.160.552.68%30.51%6.89%11/5/2025 (Estimated)

Latest FDMT, PAHC, ABCL, and EVO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/27/2025Q4 2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.52$0.57+$0.05$0.42$362.24 million$378.70 million
8/11/2025Q2 2025
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
-$0.88-$0.98-$0.10-$0.98$0.52 million$0.01 million
8/7/2025Q2 2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$0.17-$0.12+$0.05-$0.12$7.55 million$17.08 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/AN/AN/AN/AN/A
Evotec AG stock logo
EVO
Evotec
N/AN/AN/AN/AN/A
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.26%N/A61.54%N/A

Latest FDMT, PAHC, ABCL, and EVO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/29/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.121.71%9/3/20259/3/20259/24/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/A
11.07
11.07
Evotec AG stock logo
EVO
Evotec
0.42
1.58
1.49
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
N/A
8.75
8.75
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.67
2.91
1.23

Institutional Ownership

CompanyInstitutional Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
61.42%
Evotec AG stock logo
EVO
Evotec
5.81%
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
99.27%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%

Insider Ownership

CompanyInsider Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
28.90%
Evotec AG stock logo
EVO
Evotec
1.00%
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
9.60%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
50.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
500298.83 million212.47 millionOptionable
Evotec AG stock logo
EVO
Evotec
4,827355.11 million351.56 millionNot Optionable
4D Molecular Therapeutics, Inc. stock logo
FDMT
4D Molecular Therapeutics
12046.70 million42.22 millionOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1,94040.53 million20.24 millionOptionable

Recent News About These Companies

Phibro: Fiscal Q4 Earnings Snapshot
Phibro (PAHC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
A Look Ahead: Phibro Animal Health's Earnings Forecast
Q4 EPS Forecast for Phibro Animal Health Reduced by Analyst

New MarketBeat Followers Over Time

Media Sentiment Over Time

AbCellera Biologics stock logo

AbCellera Biologics NASDAQ:ABCL

$4.30 -0.05 (-1.03%)
As of 03:52 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Evotec stock logo

Evotec NASDAQ:EVO

$3.55 +0.06 (+1.72%)
As of 03:50 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

4D Molecular Therapeutics stock logo

4D Molecular Therapeutics NASDAQ:FDMT

$6.23 -0.23 (-3.58%)
As of 03:52 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$38.14 +5.94 (+18.44%)
As of 03:52 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.